Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (991-1000 of 1,095) with videos related to

Pageof 110
Sort By:
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Journal of Hepatology|June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAsJordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
The Journal of Infectious Diseases|May 17, 2021
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis BYao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, et al.
HGG Advances|June 30, 2024
Stratified analyses refine association between TLR7 rare variants and severe COVID-19Jannik Boos, Caspar I van der Made, Gayatri Ramakrishnan, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Pageof 110

Showing results (991-1000 of 1,095) with videos related to

Sort By:
Pageof 110
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Journal of Hepatology|June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAsJordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
The Journal of Infectious Diseases|May 17, 2021
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis BYao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, et al.
HGG Advances|June 30, 2024
Stratified analyses refine association between TLR7 rare variants and severe COVID-19Jannik Boos, Caspar I van der Made, Gayatri Ramakrishnan, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Pageof 110